XTX Topco Ltd Purchases 19,721 Shares of GSK plc (NYSE:GSK)

XTX Topco Ltd increased its stake in shares of GSK plc (NYSE:GSK - Free Report) by 68.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,325 shares of the pharmaceutical company's stock after acquiring an additional 19,721 shares during the quarter. XTX Topco Ltd's holdings in GSK were worth $1,976,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of GSK. Eastern Bank purchased a new position in shares of GSK in the third quarter worth $26,000. Concord Wealth Partners increased its position in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock valued at $32,000 after acquiring an additional 547 shares during the period. Ashton Thomas Private Wealth LLC bought a new position in shares of GSK during the second quarter valued at about $37,000. Fortitude Family Office LLC purchased a new stake in shares of GSK during the third quarter worth about $42,000. Finally, PrairieView Partners LLC purchased a new position in GSK during the 2nd quarter valued at about $47,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GSK has been the topic of several research analyst reports. Jefferies Financial Group cut GSK from a "buy" rating to a "hold" rating and reduced their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. StockNews.com lowered shares of GSK from a "strong-buy" rating to a "buy" rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Finally, Barclays raised GSK to a "hold" rating in a research report on Tuesday, August 27th. Seven analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Stock Performance

Shares of GSK stock traded up $0.04 during trading hours on Friday, reaching $34.57. The company had a trading volume of 3,702,817 shares, compared to its average volume of 6,373,853. The firm has a market cap of $71.65 billion, a PE ratio of 22.45, a price-to-earnings-growth ratio of 1.32 and a beta of 0.64. The business has a fifty day moving average price of $36.66 and a 200-day moving average price of $39.57. GSK plc has a one year low of $32.83 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.55%. This is a boost from GSK's previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, November 15th. GSK's dividend payout ratio is presently 98.70%.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the company's stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company's stock, valued at $134,205,528. The trade was a 19.97 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.00% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.